Fogelman D, et al. - Given that the Janus kinase/signal transducer and activator of transcription (JAK-STAT) signaling pathway plays a key role in the systemic inflammatory response in many cancers, including colorectal cancer (CRC). In patients with relapsed/refractory metastatic CRC, researchers assessed the addition of ruxolitinib, a potent JAK1/2 inhibitor, to regorafenib. This two-part, multicenter, phase 2 study was conducted in 95 sites in North America, European Union, Asia Pacific, and Israel. In patients with relapsed/refractory metastatic CRC, an addition of ruxolitinib to regorafenib did not exhibit increased safety concerns. The results obtained from the study indicate that this combination did not improve overall survival (OS)/progression-free survival (PFS) vs regorafenib plus placebo.